Cytosorbents Corporation (CTSO)
NASDAQ: CTSO · Real-Time Price · USD
1.010
+0.010 (1.00%)
Apr 1, 2025, 10:11 AM EDT - Market open
Cytosorbents Revenue
In the year 2024, Cytosorbents had annual revenue of $35.59M, down -2.08%. Cytosorbents had revenue of $6.52M in the quarter ending December 31, 2024, with 91.65% growth.
Revenue (ttm)
$35.59M
Revenue Growth
+14.51%
P/S Ratio
1.53
Revenue / Employee
$191,368
Employees
186
Market Cap
55.23M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 35.59M | -754.86K | -2.08% |
| Dec 31, 2023 | 36.35M | 1.66M | 4.79% |
| Dec 31, 2022 | 34.69M | -8.48M | -19.64% |
| Dec 31, 2021 | 43.17M | 2.16M | 5.27% |
| Dec 31, 2020 | 41.00M | 16.06M | 64.35% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
CTSO News
- 14 hours ago - Cytosorbents Corporation (CTSO) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 18 hours ago - CytoSorbents Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights - PRNewsWire
- 11 days ago - CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit - PRNewsWire
- 4 weeks ago - CytoSorbents Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller - GlobeNewsWire
- 3 months ago - CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2024 Product Revenue - GlobeNewsWire
- 3 months ago - CytoSorbents to Host Investor Meetings in San Francisco During J.P. Morgan Healthcare Conference Week - GlobeNewsWire
- 5 months ago - CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India - GlobeNewsWire
- 5 months ago - Cytosorbents Corporation (CTSO) Q3 2024 Earnings Call Transcript - Seeking Alpha